Kevin Kabler concentrates his practice on patent prosecution, intellectual property due diligence, patent analysis, and strategic patent counseling for academic, venture capital and biotechnology clients.
Among the technologies with which Kevin has experience are siRNA, clean-tech, stem cells, immunotherapy, monoclonal antibodies, small molecules, polypeptides, oligonucleotides, viruses, vaccines, transgenic animals, and microarrays.
In 2007, Kevin began his career at Fenwick & West as a patent agent. Prior to joining Fenwick & West, Kevin was a postdoctoral fellow in the lab of Nobel Laureate J. Michael Bishop at the University of California, San Francisco.
Kevin is a co-inventor on multiple patents and has published numerous scientific papers in leading peer-reviewed journals including Nature Medicine and Nature Biotechnology.
- Human SOCS1 controls immunostimulatory activity of monocyte-derived dendritic cells, Cancer Research, 2009 Oct. 15;69(20):8076-84
- A20 is an antigen presentation attenuator, and its inhibition overcomes regulatory T cell-mediated suppression, Nature Medicine, 2008 Mar.:14(3):258-265
- Dendritic cell-based tumor vaccines and antigen presentation attenuators, Molecular Therapy, 2006 May;13(5):850-8
- Inhibition of antigen presentation attenuators to augment vaccines, Current Opinion in Molecular Therapeutics, 2006 Feb.;8(1):24-30
- SOCS1 restricts dendritic cell's ability to break self-tolerance and induce anti-tumor immunity by controlling IL-12 production and signaling, Journal of Clinical Investigation, 2006 Jan.;116(1):90-100
- An alternative and effective HIV vaccination approach based on inhibition of antigen presentation attenuators in dendritic cells, PLoS Medicine, 2006 Jan.:3(1)e11
- Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity, Nature Biotechnology, 2004 Dec.;22(12):1546-53